Haven't seen anyone mention that the rights attributable to the Renounceable Entitlement Issue are currently trading (ASX Code: CUERB) as of yesterday - albeit for a limited time. CUE was a top 3 stock pick recommendation (spec) by a Hogan Partners analyst/broker featured in The Sunday Times Business section on Sunday just gone. CUE will shine in this current environment because it wasn't inflated, hyped or overbought prior to the Correction. Been at these levels on or around for the last twelve months and the current drilling is sure to fire up the SP with continued good news. The Rights Entitlement is fully backed by Todds, so that's another $23 Million in the Bank - guaranteed. The future looks outstanding and it can only go one way from here in my opinion - UP. The time for patient holders to be well rewarded is almost here, but then again, with what CUE has got happening 2006,2007,2008, I can't see myself selling out short on this one. wrxsti
CUE Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
